International Journal of Hepatology Research

ISSN Print: 2664-6595
ISSN Online: 2664-6609
IJHR 2022; 4(1): 08-11
www.hepatologyjournal.in
Received: 17-11-2021
Accepted: 18-12--2021

Pascal Ndayishimiye
Faculty of Gastroenterology, Ngozi Polytechnic College of Medical Sciences, Ngozi, Burundi, East Africa

Alice Ntahombaye
Faculty of Gastroenterology, Ngozi Polytechnic College of Medical Sciences, Ngozi, Burundi, East Africa

Eric Habonimana
Faculty of Gastroenterology, Ngozi Polytechnic College of Medical Sciences, Ngozi, Burundi, East Africa

Corresponding Author:
Pascal Ndayishimiye
Faculty of Gastroenterology, Ngozi Polytechnic College of Medical Sciences, Ngozi, Burundi, East Africa

Chronological developments in hepatocellular carcinoma staging and classification systems

Pascal Ndayishimiye, Alice Ntahombaye and Eric Habonimana

DOI: https://doi.org/10.33545/26646595.2022.v4.i1a.27

Abstract
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, accounting for a substantial global disease burden. Over the decades, the classification and staging of HCC have undergone significant evolution, driven by advances in understanding tumor biology, liver function, and diagnostic technologies. This paper reviews the chronological development of HCC staging and classification systems, from early models like the TNM and Okuda systems to the more comprehensive Barcelona Clinic Liver Cancer (BCLC) staging system, and the recent integration of molecular and imaging-based approaches. The paper also highlights the future potential of personalized medicine, with molecular profiling and liquid biopsies offering new avenues for classifying HCC more precisely.

Keywords: Hepatocellular carcinoma (HCC), staging systems, TNM, Okuda classification, BCLC, molecular profiling, liver function, imaging, personalized medicine

Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and represents a significant global health challenge. It accounts for approximately 75-85% of liver cancers and is the sixth most common cancer worldwide, with more than 800,000 new cases diagnosed annually. The incidence of HCC is particularly high in regions with endemic hepatitis B and C infections, such as East Asia and sub-Saharan Africa, although non-viral causes, such as alcohol abuse and non-alcoholic fatty liver disease (NAFLD), are becoming increasingly significant in Western countries. The complexity of HCC, driven by its heterogeneity in tumor biology, etiology, and patient profiles, demands a robust and dynamic approach to classification and staging.

Accurate classification and staging of HCC are crucial for determining the prognosis and selecting appropriate treatment options. Early-stage HCC patients may benefit from curative treatments such as surgical resection, liver transplantation, or ablation therapies, while advanced-stage patients often require palliative care or systemic treatments like targeted therapy or immunotherapy. Given the varied nature of the disease, a reliable staging system that takes into account both tumor characteristics and liver function is essential for guiding clinical decision-making.

Historically, early classification systems for HCC focused primarily on tumor size and number, with limited consideration for the underlying hepatic function or the patient's overall health status. This led to the development of several staging systems that aimed to incorporate both tumor biology and liver function, as liver cirrhosis is a major comorbidity in many HCC patients. Over time, these systems have evolved to reflect advancements in imaging techniques, molecular profiling, and clinical outcomes, making HCC staging more comprehensive and personalized.

One of the earliest structured staging systems for HCC was the TNM (Tumor, Node, Metastasis) system, developed in the 1970s. The TNM system, widely used in various cancers, classifies tumours based on the size and extent of the primary tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). While the TNM system provides valuable anatomical information about the tumor, it falls short in evaluating the liver's functional status and the patient's overall health, both of which are critical in managing HCC. As a result, this system has gradually been supplemented by more comprehensive models that integrate liver function and patient performance.

In the 1970s, the Child-Pugh classification system emerged to assess liver function in patients with cirrhosis. This system, though not developed specifically for HCC, became widely adopted due to its ability to evaluate liver function, which is crucial for understanding the prognosis of HCC patients. The Child-Pugh system categorizes liver function into three classes (A, B, and C) based on five parameters: serum bilirubin, serum albumin, prothrombin time, the presence of ascites, and hepatic encephalopathy. This allowed clinicians to evaluate not only the tumor but also the liver's ability to tolerate treatment. However, the Child-Pugh system does not address tumor characteristics directly, prompting the development of more integrated staging systems.

In the late 1970s, the Okuda staging system was introduced, combining tumor size, the presence of ascites, and liver function parameters (serum albumin and bilirubin levels) into a single staging model for HCC. The Okuda system was an important step forward, as it recognized the need to evaluate both the tumor burden and liver function simultaneously. This two-pronged approach provided a clearer prognosis for patients and guided treatment options, though it still lacked the granularity provided by more modern staging systems.

The most significant development in HCC classification came in the 1990s with the creation of the Barcelona Clinic Liver Cancer (BCLC) staging system, which remains one of the most widely used systems today. The BCLC system classifies patients based on tumor stage, liver function (using the Child-Pugh score), and the patient's performance status (measuring their general well-being and ability to carry out daily activities). This multidimensional approach allows clinicians to better stratify patients into groups that are more likely to benefit from curative, palliative, or systemic treatments. For example, patients with very early-stage HCC are candidates for curative therapies like resection or transplantation, while those with advanced-stage HCC may receive targeted therapies like sorafenib.

In recent years, the understanding of HCC has expanded beyond traditional staging systems, with advances in molecular biology and genomics playing an increasingly important role. Molecular profiling has revealed that HCC is not a uniform disease, but rather a collection of molecularly distinct subtypes with different genetic, epigenetic, and immune profiles. These molecular differences have significant implications for prognosis and treatment response. For instance, mutations in genes like TP53 and CTNNB1 have been shown to correlate with specific clinical outcomes and may influence the effectiveness of therapies, particularly targeted treatments and immunotherapies.

Moreover, imaging technologies have advanced significantly, enhancing the ability to classify and monitor HCC. Techniques such as contrast-enhanced ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) provide detailed information on tumor size, vascular invasion, and the presence of extra hepatic spread. In particular, the Liver Imaging Reporting and Data System (LI-RADS) has been developed to standardize the reporting of imaging findings for HCC, helping to reduce variability in diagnosis and improve treatment planning.

Given these advancements, the classification and staging of HCC are likely to continue evolving. The integration of molecular data, imaging techniques, and patient performance metrics is expected to further personalize treatment strategies and improve outcomes. Emerging technologies, such as liquid biopsies, may also offer non-invasive ways to monitor tumor progression and treatment response, making classification even more precise.

This paper aims to chronicle the development of HCC classification systems, tracing their evolution from early anatomical models to modern approaches that integrate molecular, clinical, and imaging data. By examining the progression of these systems, this study provides a comprehensive understanding of how HCC classification has adapted to meet the demands of a more personalized and precise approach to cancer care.

Main Objective

The main objective of this paper is to chronologically analyze the development of hepatocellular carcinoma (HCC) staging and classification systems, examining their evolution from anatomical models to modern molecular and imaging-based approaches.

Early Classification Systems

The earliest attempts to classify liver cancers, including HCC, were largely based on the size and number of tumors, without considering the underlying liver function or the patient's overall health status. These early systems were rudimentary and focused primarily on anatomical factors such as the size of the tumor (small vs. large) and whether the tumor was solitary or multifocal. While these factors were important, they provided an incomplete picture of the disease's progression and its potential impact on survival outcomes.

One of the first structured approaches to classifying HCC emerged in the 1970s with the development of the TNM (Tumor, Node, and Metastasis) staging system, which was adopted by the American Joint Committee on Cancer (AJCC). The TNM system was designed to categorize tumors based on their size (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). Although the TNM system was useful in assessing the anatomical extent of the disease, it failed to account for the underlying liver function, which plays a crucial role in the prognosis and treatment of HCC patients. This limitation prompted the development of more sophisticated staging systems that incorporated liver function assessment.

Incorporating Liver Function: The Child-Pugh Classification

In the 1970s, the Child-Pugh classification system was introduced to assess liver function in patients with cirrhosis, which is a common underlying condition in HCC patients. The Child-Pugh system evaluates five clinical and laboratory parameters: serum bilirubin levels, serum albumin levels, prothrombin time, the presence of ascites, and hepatic encephalopathy. Patients are classified into three categories: Child-Pugh Class A (well-compensated liver function), Class B (moderately impaired liver function), and Class C (severely impaired liver function). This system provided an important tool for evaluating the prognosis of HCC patients, as liver function is a critical determinant of treatment options and survival.

Although the Child-Pugh classification was not initially developed specifically for HCC, it became an integral

component of HCC staging due to the high prevalence of cirrhosis in these patients. However, while the Child-Pugh system was effective in evaluating liver function, it did not fully address tumor-related factors such as size, number, or vascular invasion.

Development of the Okuda Staging System

In the late 1970s, the Okuda staging system was introduced to bridge the gap between tumor characteristics and liver function. Developed by Okuda and colleagues, this system combined tumor size, the presence of ascites, and liver function parameters (serum albumin and bilirubin levels) to stage HCC patients. The Okuda staging system classified patients into three stages, with Okuda stage I representing early-stage disease with good liver function, and Okuda stage III representing advanced disease with poor liver function. The Okuda system marked a significant advancement by integrating both tumor burden and liver function, but it was still relatively simple and did not account for modern imaging findings or emerging molecular insights into HCC.

The Barcelona Clinic Liver Cancer (BCLC) Staging System

The 1990s saw the development of the Barcelona Clinic Liver Cancer (BCLC) staging system, which remains one of the most widely used HCC staging systems today. The BCLC system incorporates tumor characteristics, liver function (using the Child-Pugh classification), and performance status (a measure of the patient's overall health and ability to carry out daily activities). This comprehensive approach allows for a more personalized assessment of prognosis and treatment options.

The BCLC system categorizes HCC into five stages: very early (0), early (A), intermediate (B), advanced (C), and terminal (D), with each stage corresponding to specific treatment recommendations. For example, very early-stage HCC is typically managed with curative therapies such as surgical resection or liver transplantation, while advanced-stage HCC is more likely to be treated with systemic therapies like sorafenib. The BCLC system's integration of tumor burden, liver function, and overall patient health marked a significant evolution in the classification of HCC, allowing for more tailored treatment strategies.

Emerging Molecular Classification Systems

With the advent of molecular biology and genomic research in the early 21st century, it became clear that HCC is not a uniform disease. Advances in molecular profiling have revealed that HCC encompasses a range of molecular subtypes with distinct genetic and epigenetic alterations. These molecular differences have important implications for prognosis and treatment response, paving the way for the development of molecular classification systems for HCC.

In recent years, molecular classification systems based on gene expression patterns, mutations in specific oncogenes or tumor suppressor genes (such as TP53 and CTNNB1), and immune-related markers have gained traction. These molecular profiles have been linked to distinct clinical outcomes and responses to targeted therapies and immunotherapies. For instance, certain molecular subtypes of HCC are more likely to respond to immune checkpoint inhibitors, highlighting the potential for personalized medicine in HCC management.

The Role of Imaging in Modern Classification

Alongside molecular advancements, imaging techniques have also evolved to play a crucial role in the classification of HCC. Modern imaging modalities such as contrast-enhanced ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) provide detailed information on tumor size, vascular invasion, and extra hepatic spread. The Liver Imaging Reporting and Data System (LI-RADS) was developed to standardize the reporting of imaging findings for HCC. LI-RADS categorizes liver nodules based on their likelihood of being HCC, ranging from benign to definitely HCC. This imaging-based classification complements traditional clinical staging systems and helps guide treatment decisions.

Current and Future Directions

Today, the classification of HCC involves a combination of clinical, radiological, and molecular factors. The BCLC staging system remains the gold standard for guiding treatment decisions in clinical practice, but there is increasing recognition of the need for more personalized approaches that take into account the molecular heterogeneity of HCC. As molecular profiling becomes more accessible, future classification systems are likely to integrate genetic, epigenetic, and immunological markers with traditional clinical parameters to provide a more comprehensive assessment of the disease.

In addition, ongoing research into liquid biopsies-non-invasive tests that detect circulating tumor DNA or other biomarkers in the blood-holds promise for refining HCC classification and monitoring treatment response. These developments are expected to further enhance the precision of HCC staging and treatment planning in the coming years.

Conclusion

The classification and staging of hepatocellular carcinoma have evolved significantly over the past few decades. Early systems focused primarily on tumor size and number, but advancements in understanding liver function, molecular biology, and imaging have led to more sophisticated approaches. The BCLC staging system, with its integration of tumor characteristics, liver function, and performance status, remains the cornerstone of HCC classification. However, the emergence of molecular subtypes and advanced imaging techniques is reshaping the way HCC is classified, paving the way for more personalized treatment strategies. As our understanding of HCC continues to grow, future classification systems are likely to incorporate even more detailed molecular and clinical data, offering patients better prognostic information and more targeted therapeutic options.

References

1. U.S. Department of Energy. Quadrennial Technology Review: Chapter 3 - Enabling Modernization of the Electric Power System. U.S. Department of Energy; c2015. Available from: https://www.energy.gov
2. U.S. Department of Energy. Benefits of Demand Response in Electricity Markets and Recommendations for Achieving Them. U.S. Department of Energy; c2012. Available from: https://www.energy.gov
3. Lawrence Berkeley National Laboratory. The Cost of Power Interruptions to Electricity Consumers in the

United States. Lawrence Berkeley National Laboratory; c2020. Available from: https://emp.lbl.gov
4. Brattle Group. The National Potential for Demand Response: The Transition to Dynamic Pricing and Time-Varying Rates. Brattle Group; c2019. Available from: https://www.brattle.com
5. Electric Power Research Institute (EPRI). Assessing the Costs and Benefits of Smart Meter Investments. EPRI; c2019. Available from: https://www.epri.com
6. U.S. Energy Information Administration (EIA). Residential Energy Consumption Survey. EIA; 2020. Available from: https://www.eia.gov
7. Federal Energy Regulatory Commission (FERC). Assessment of Demand Response and Advanced Metering. FERC; c2019. Available from: https://www.ferc.gov
8. Solar Energy Industries Association (SEIA). U.S. Solar Market Insight Report. SEIA; c2021. Available from: https://www.seia.org
9. International Renewable Energy Agency (IRENA). Smart Grids and Renewables: A Guide for Effective Deployment. IRENA; c2017. Available from: https://www.irena.org
10. National Renewable Energy Laboratory (NREL). Distributed Solar Photovoltaics Economic Impact Analysis. NREL; c2020. Available from: https://www.nrel.gov
11. U.S. Department of Energy. Smart Grid Economic Development: The Role of Smart Grids in Economic Growth. U.S. Department of Energy; c2010. Available from: https://www.energy.gov
12. Electric Power Research Institute (EPRI). The Economic Impact of Power Interruptions on the U.S. Economy. EPRI; c2018. Available from: https://www.epri.com
13. Electric Power Research Institute (EPRI). Reliability of the U.S. Electric Grid: Assessment and Recommendations. EPRI; c2019. Available from: https://www.epri.com